U-Neuron Biomedical

U-Neuron Biomedical Liabilities

The The Liabilities of U-Neuron Biomedical (6973.TWO) as of Nov 5, 2026 is 35.27 M TWD. In the previous year, The Liabilities was 31.20 M TWD — a change of 13.04% (higher).

Liabilities

35.27 MTWD

YoY

13.04%

Last updated:

In 2024, U-Neuron Biomedical's total liabilities amounted to 35.27 M TWD, a 13.04% difference from the 31.20 M TWD total liabilities in the previous year.

The U-Neuron Biomedical Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2021
15.94 M TWD
Jan 1, 2022
23.04 M TWD
Jan 1, 2023
31.20 M TWD
Jan 1, 2024
35.27 M TWD
The U-Neuron Biomedical Liabilities history
YEARLiabilitiesYoY
35.27 MTWD+13.04%
31.20 MTWD+35.44%
23.04 MTWD+44.52%
15.94 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc develops cosmetics, health care consumer products, and new drugs using allogeneic amniotic fluid stem cells and their derivatives. The company's new drug portfolio includes UA002 for erectile dysfunction and UB003 for dry eye, while its cosmetic line features masks, essences, and creams for anti-aging, repairing, and moisturizing. These products are primarily sold within Taiwan, targeting domestic consumers seeking medical beauty and health care solutions. The company leverages the regenerative properties of amniotic fluid stem cells to create applications in both therapeutic and cosmetic segments. The business model focuses on developing products around deer amniotic fluid stem cell derivatives for cosmetics, which form the core of its health care consumer product line. UA002 and UB003 represent the company's pharmaceutical offerings, addressing specific medical conditions with stem cell-based treatments. Domestic sales drive revenue, with no mention of international markets or additional distribution channels in the provided description. U-Neuron Biomedical Inc's revenue streams come from the domestic sale of its cosmetic products and pharmaceuticals. The company's product segments are clearly divided between new drug development and cosmetic/health care consumer products, with each segment utilizing stem cell technology in different applications. Sales are concentrated within Taiwan, where the company's products meet local demand for regenerative medicine and beauty solutions. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing U-Neuron Biomedical's Liabilities

U-Neuron Biomedical's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating U-Neuron Biomedical's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing U-Neuron Biomedical's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

U-Neuron Biomedical's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in U-Neuron Biomedical’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about U-Neuron Biomedical stock

The Liabilities of U-Neuron Biomedical is 35.27 M TWD in 2024.

The Liabilities of U-Neuron Biomedical changed from 31.20 M TWD to 35.27 M TWD, representing a 13.04% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's U-Neuron Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — U-Neuron Biomedical

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — U-Neuron Biomedical